StemCell Therapy

DOYLESTOWN, Pa., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (KLFE) (Kannalife or the Company), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Healths (NIH) National Institute on Drug Abuse (NIDA). The study was performed by Kannalife and the Lewis Katz School of Medicine at Temple University (LKSOM) to assess KLS-13019, the Companys patented cannabidiol (CBD)-like molecule as a potential treatment of neuropathic pain and drug dependence.

The pre-clinical grant study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN).

The animal model portion of the study was conducted by Sara Jane Ward, PhD, Assistant Professor of Pharmacology at LKSOM. Dr. Ward had independently begun the research focused on CBD for the potential treatment of CIPN in 2010 at LKSOM and published three papers on the subject prior to beginning the collaboration with Kannalife.

Im very excited about the results we have obtained with KLS-13019 to date. In our model, KLS-13019 is at least as effective as CBD to prevent neuropathic pain; however, KLS-13019 is also effective to reverse neuropathic pain as a consequence of cancer chemotherapy, whereas CBD was not effective under our test conditions. We will continue to explore the possibility that KLS-13019 could be even safer and more effective than CBD, stated Dr. Ward.

Kannalife performed pharmacology studies on the mechanism of action of KLS-13019 and its effects on the sodium-calcium exchanger (mNCX-1), an important regulator of mitochondrial function. Results of the studies performed by Douglas Brenneman, PhD, for Kannalife, have been published in the Journal of Molecular Neuroscience in a paper titled, Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity.

For KLS-13019 treatment of CIPN, significant progress has been made in identifying a molecular mechanism of protection from the complex effects of paclitaxel-induced damage of sensory nerve cells, stated Dr. Brenneman.

The completed study could lead to a Phase 2 grant and further advances Kannalifes belief that KLS-13019 could become a viable drug candidate, and an alternative to opioids, as a treatment for patients suffering from CIPN, and chronic pain management. CIPN is a disabling pain condition that afflicts between 30-40 percent of patients undergoing chemotherapy, for which there is no effective prevention strategy and treatment of established chronic CIPN is limited.1 Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases of CIPN.2

The global market for neuropathic pain was valued at more than $5 billion in 2015, and in 2016, CIPN accounted for more than 42 percent of market revenue. Its estimated that by 2024, the total global neuropathic pain market will be worth more than $8.3 billion.3-4

The global opioids drug market was valued at $22.85 billion in 2017 and is expected to reach $32.6 billion by 2026, at a CAGR of 4.54% during a forecast period. Opioids are mainly used in cancer pain management and end-stage diseases in which painkilling care is required. The rising prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and increasing approval rate of abuse-deterrent formulations of opioid drugs are major driving factors of the global opioids drugs market. Extensive misuse of opioids, the growing incidence of death related to opioid overdose, and the rising number of lawsuits against opioid manufacturers are hindering the growth of the market. 5

A recently released animated video from Kannalife describes a Mechanism of Action (MOA) for KLS-13019. This video can be accessed on the Companys website at http://www.kannalife.com and via Vimeo at https://vimeo.com/371214213.

Research reported in this press release was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the amount of $299,916 under award number 1R41DA044898-01.

Story continues

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Temple HealthTemple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHSs physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.

Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.

It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

About KLS-13019KLS-13019 is Kannalifes leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Companys family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

References

CONTACT:

Public Relations:

Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Mike Mulvihill, Senior Counsel of PadillaP: 804-334-2292E: mike.mulvihill@padillaco.com

Investor Relations:Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

See the rest here:
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential...

Diabetic neuropathy is a complication that occurs due to prolonged excessive blood sugar level. It basically damages the nerves present in legs and hands. Depending on the nerves, diabetic neuropathy has affected, you feel the symptom ranging from pain and numbness in legs to digestive problems, and cardiovascular issues.

If you are suffering from diabetes and is not able to control the blood sugar level, the walls of your blood vessels may become weak and get damaged. Apart from diabetes, a combination of factors including smoking, drinking alcohol, genetics, and inflammation in nerves can cause nerve damage. In case of non-availability of timely treatment, the condition may aggravate and lead to various complications. Here, we tell you about them.

Also known as a neuropathic joint, Charcot joint is a progressive joint disorder that causes discomforting pain sensation. It causes joints to deteriorate that shows symptoms including swelling in joints, instability, and joint deformity.

If diabetic neuropathy damages the nerves controlling your bladder, you wont be able to empty it completely. This can lead to the accumulation of bacteria in the bladder and kidneys. This is what is called urinary tract infection. This can make you disable to control the muscles that release urine and feel urination. This can further lead to leakage and unwanted embarrassment.

In case diabetic neuropathy leads to the damage of the nerves controlling the functions of your digestive tract, you will experience constipation, diarrhoea or both. Nerve damage associated with diabetes has been found to cause a condition called gastroparesis in which your stomach either empties too fast or not at all. This can lead to an excessive increase in blood sugar level.

Nerve damage has been found to affect the functions of your sweat gland and thus makes it problematic to control body temperature. If you have autonomic neuropathy, you will experience too much sweating. Notably, too little or no sweating can be debilitating.

Continue reading here:
Suffering From Diabetic Neuropathy? Beware of These Complications - India.com

Flex Wheeler has gone through a considerable amount over the past several months. It appears that his leg amputation was only one of the hardships that the bodybuilding legend has been going through physically. Now it appears that Flex Wheeler has been afflicted with another ailment.

The veteran bodybuilder has apparently been dealing with neuropathy. But rather than let this nerve damage diagnosis get him down, Flex Wheeler is once again showing the heart and resolve of a champion.

If a leg amputation couldnt keep Flex Wheeler out of the gym then you can bet a little nerve damage isnt going to stop the legend. Here he is hitting the gym to work back like a true savage.

From what everything Flex Wheeler has been through, it appears that nothing can hold this IFBB legend back.

For more news and updates, follow Generation Iron on Facebook, Twitter, and Instagram.

Managing Editor at Generation Iron, Jonathan Salmon is a writer, martial arts instructor, and geek culture enthusiast. Check out his Instagram, Twitter, Facebook, and Sound Cloud for in-depth MMA analysis.

Header image courtesy of Instagram

View post:
Flex Wheeler Battles Through Nerve Damage, Hits the Gym to Train Back - generationiron.com

Dublin, Feb. 12, 2020 (GLOBE NEWSWIRE) -- The "In-Vitro Toxicology/Toxicity Testing Market by Product & Services, Toxicity Endpoint & Test (Carcinogenicity, Dermal Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays), Industry (Pharmaceutical, Cosmetics), Region-Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The In-Vitro Toxicology Testing Market is Expected to Reach USD 12.7 Billion by 2024 from an Estimated USD 8.1 Billion in 2019, at a CAGR of 9.3%.

The opposition to animal testing, technological advancements, and increasing R&D expenditure to detect toxicity at an early stage during drug development are the primary growth factors for this industry.

The increasing focus of the pharmaceutical and cosmetics industries on using in-vitro methods for product testing along with the improvement in silico methods for predictive toxicology studies are expected to offer significant growth opportunities for players in this market. However, the dearth of skilled professionals is a substantial market challenge.

The software segment is expected to grow at the highest rate during the forecast period.

Based on the product & service, the in-vitro toxicology testing market is segmented into consumables, assays, equipment, software, and services. The software segment is projected to witness the highest growth in the in-vitro toxicology testing market during the forecast period.

Growth in this segment is driven mostly by the rising number of new technologies to develop in-vitro signatures and computational models capable of predicting in vivo responses. Also, the increasing use of the latest software in the industry and the academia to predict toxicity by comparing the data of new substances with other structurally or biologically similar compounds, are expected to drive the growth of this segment.

The ADME segment is expected to account for the largest market share in 2018.

Based on toxicity endpoints & tests undertaken across all industries, the in-vitro toxicity testing market is segmented into ADME; skin irritation, corrosion, and sensitization; genotoxicity; cytotoxicity; ocular toxicity; organ toxicity; phototoxicity; dermal toxicity; and other endpoints & tests. The ADME segment accounted for the largest share of the in-vitro toxicity testing market in 2018. This can be attributed to the high adoption during the drug development process with the advantage of producing highly reproducible & accurate data.

Toxicogenomics is expected to grow at the highest rate during the forecast period.

The toxicogenomics segment is expected to grow at the highest CAGR during the forecast period, primarily due to the technological advancements taking place in the field of proteomics and genomics. Also, the improvements in proteomic technologies are enhancing the study of gene & protein activity during toxicity analysis. Technological advancements taking place in the field of proteomics and genomics will further drive the growth of this segment in the coming years.

Europe is expected to hold the largest share for players operating in the in-vitro toxicology testing market.

Europe accounted for the largest share of the in-vitro toxicology testing market in 2018. Factors such as high adoption of in-vitro toxicology testing assays and services in the cosmetics and chemical industries after the ban on animal testing in the region are among the few factors expected to contribute to the growth of this market.

Story continues

Market Dynamics

Market Drivers

Opposition to Animal Testing

Technological Advancements

R&D Toward Early Stage Toxicity Detection

Market Restraints

Reluctance of Regulatory Authorities to Consider Alternative Methods for Proving Safety and Efficacy

Failure to Establish the Intricacies of in Vivo Conditions, In Vitro

Lack of In Vitro Models to Study Complex Endpoints

Market Opportunities

Market Challenges

Company Profiles

Bio-Rad Laboratories, Inc.

Bioivt

Catalent, Inc.

Charles River Laboratories International, Inc.

Covance, Inc.

Creative Bioarray

Creative Biolabs

Cyprotex PLC

Eurofins Scientific SE

GE Healthcare

Gentronix Limited

GVK Biosciences Private Limited

Insphero

MB Research Laboratories

Merck KGaA

Promega Corporation

Qiagen N.V.

SGS S.A.

Shanghai Medicilon Inc.

Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/gea7u2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

More here:
In-Vitro Toxicology/Toxicity Testing Market Trends, 2019-2024 - Increasing Focus on Drug Discovery and Personalized Medicine Using In Vitro Methods -...

Global cell isolation market is expected to attain a CAGR of 18.8% during the forecast period.

The global cell isolation market accounted for $4.6 billion revenue in 2017, and it is expected to attain a CAGR of 18.8% during the forecast period (20182023). The demand for cell isolation products and services is increasing due to the rise in requirement for biopharmaceuticals, growing research activities in personalized medicine, and increasing government funding for research.

Cell isolation is the separation of one or multiple types of cells from a heterogenous cell population.

It has become an integral step in biological research, and routine diagnosis and treatment of certain diseases. Some cell types, such as blood cells, naturally exist in a separated form and thus can be isolated by employing centrifugation, whereas some others exist as solid tissues that require specific techniques to isolate the individual cell type.

The global cell isolation market is witnessing growth owing to the rising demand for biopharmaceutical products derived from natural sources, such as plants, animals, and humans, that are easier to manufacture than conventional pharmaceuticals.

Report at:www.psmarketresearch.com/market-ort-sample

The prevalence of neurological diseases, such as Parkinsons disease, amyotrophic lateral sclerosis, spinal cord injury, and autoimmune conditions, namely type 1 diabetes, multiple sclerosis, and Crohns disease is rising. This, coupled with the increasing awareness about these diseases, is impelling the governments of many countries to invest in biomedical research and related technology, thus giving a boost to growth of the cell isolation market and biopharmaceutical production as well.

People in developed countries are shifting toward personalized medicine, owing to their awareness and means to afford personalized treatment, as they can now avail of several reimbursement schemes. The advent of new technologies, such as genetic mapping via next-generation sequencing, which helps in identifying the gene responsible for a specific disease, is boosting the personalized medicine domain.

This growth in the personalized medicine domain is impacting the cell isolation market positively.

GLOBAL CELL ISOLATION MARKET SEGMENTATION

Market Segmentation by Product

Report: http://www.psmarketresearch.com/send-enion-market

Market Segmentation by Cell Type

Market Segmentation by Technique

Market Segmentation by Application

Market Segmentation by End User

This email address is being protected from spambots. You need JavaScript enabled to view it.

Continue reading here:
Growing Biomedical Research and Focus on Personalized Medicine to Aid Cell Isolation Market available in the latest report - WhaTech

A team of international clinicians and scientists on Wednesday published findings from a comprehensive review of more than 2,600 cancer genomes, which observers say could further pave the way for clinicians to prescribe precise treatments to cancer patients based on their genes.

The team, who published their findings in 23 papers in Nature and its affiliated journals, completed the research through a joint project of the International Cancer Genome Consortium (ICGC) and U.S.-funded Cancer Genome Atlas (TCGA) called the Pan-Cancer Analysis of Whole Genomes Project (PCAWG). The project involved more than 1,300 clinicians and scientists, including members of Harvard and the Broad Institute of MIT, from across 37 countries.

Whereas researchers in the past had only looked at 1% of the cancer genome that specifically codes for proteins, called the exome, this project analyzed the entire cancer genome. To understand this remaining 99%, a team of 16 working groups analyzed more than 2,600 whole genomes from 38 different tumor types using the field's largest publicly available whole-genome dataset. The project took six years.

The researchers were able to gain a more nuanced understanding of "driver mutations," or mutations that play a major role in driving cancer progression. While previous studies of the cancer exome had also shown common driver mutations, this study allowed the researchers to find more mutations in non-coding areas which have an impact on cancer progression. On average, the researchers found each type of cancer had four or five driver mutations. As a result of the research, only 5% of cancer tumors now have unknown genetic drivers.

These newly discovered driver mutations could potentially be new targets for new drugs and allow for more personalized care for cancer patients. Clinicians have long been frustrated that two patients with identical tumors can respond to the same treatments in different ways. This study moves the field closer to providing oncologists with a list of cancer-causing mutations that they can use to personalize treatment.

In addition, the researchers discovered a new way to "carbon date" cancer. The method allows researchers to identify old mutations involved in forming cancers and determine the relative timing between them. Using this technique, they found nearly 20% of mutations occurred years, or even decades, before the cancer was found. Fifty percent of these early mutations occurred in the same nine genes.

Gad Getz, a co-senior author of three of the papers and the director of bioinformatics at the Massachusetts General Hospital's Cancer Center and a professor of pathology at Harvard Medical School, said, "This large international effort shows the breadth of the types of research and new biological insight that are possible using whole cancer genome data."

Observers also noted that the findings could lead to better diagnostics and prevent cancer. "It's certainly true that this kind of sequencing will not mean that all cancers are cured," said Peter Campbell of the Wellcome Sander Institute, a PCAWG member. "But it points us to where we should be thinking about developing drugs for preventing resistance or treating it once it arises" (Drage O'Reilly, Axios, 2/6; McPherson, Harvard Gazette, 2/5; Kaiser, Science, 2/5).

Read the original:
A team of scientists examined more than 2600 cancer genomes. Here's what they found. - The Daily Briefing

New Jersey, United States, The report titled, Personalized Medicine Market Size and Forecast 2026 in Verified Market Research offers its latest report on the global Personalized Medicine market that includes comprehensive analysis on a range of subjects like competition, segmentation, regional expansion, and market dynamics. The report sheds light on future trends, key opportunities, top regions, leading segments, the competitive landscape, and several other aspects of the Personalized Medicine market. Get access to crucial market information. Market players can use the report back to peep into the longer term of the worldwide Personalized Medicine market and convey important changes to their operating style and marketing tactics to realize sustained growth.

Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=ITN&utm_medium=002

Top 10 Companies in the Global Personalized Medicine Market Research Report:

Global Personalized Medicine Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Personalized Medicine Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Personalized Medicine Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Personalized Medicine Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Personalized Medicine Market is segmented on the basis of product type, applications, and its end users.

Global Personalized Medicine Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=ITN&utm_medium=002

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=ITN&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

TAGS: Personalized Medicine Market Size, Personalized Medicine Market Growth, Personalized Medicine Market Forecast, Personalized Medicine Market Analysis, Personalized Medicine Market Trends, Personalized Medicine Market

Read more:
Personalized Medicine Market 2020 Booming by Size, Revenue, Trend and Top Companies 2026 - Instant Tech News

Genedata and the Crohns & Colitis Foundation completed a project aimed at advancing precision care for Crohns disease patients.Genedata, a biopharmaceutical research and development software company, worked with foundation investigators and clinicians to integrate and study multi-omic and clinical data culled from patients with Crohns, which, along with ulcerative colitis, is among the most common forms of inflammatory bowel disease (IBD).The data will be used to identify the biomarkers that can be the most useful in evaluating, within five years of IBD diagnosis, a person's risk of developing disease complications that require surgery.Crohns disease is a chronic, often debilitating disease, for which there is currently no cure, Andres Hurtado-Lorenzo, PhD, the foundations senior director of translational research, said in a press release. Despite several treatment options, currently we lack predictive tests to determine the optimal treatment strategy early in the disease process, when the opportunity to improve outcomes is greatest.""There is a significant unmet need to advance new diagnostic tools to enable precision medicine approaches and to optimize patient care according to the severity of the disease course," he said.The foundation sought help with leveraging abundant clinical and molecular data. Multi-omics is an approach in which multiple datasets (such as genes or protein profiles) are combined and analyzed for new associations.Genedata used its precision medicine software platform, Genedata Profiler, to provide data analysis that could advance biomarker research efforts. Biomarkers are useful in predicting disease trajectory, which is crucial to personalized treatment plan development.We decided to im

Read the rest here:
Precision Medicine is Focus of Genedata, Crohn's Foundation Project - IBD News Today

First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery

IRVING, Texas, Feb. 12, 2020 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research,illustrating that use of the Company's proprietary ADAPT Biotargeting System can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate (LNCaP).

Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)

The paper, "ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes," also demonstrates that the ADAPT platform can be a powerful method that allows for the enrichment of polyligands that can distinguish even between different subpopulations of the same disease.

The results show that the ADAPT Biotargeting System has the resolution and sensitivity to discover differences in protein complexes using exosomes secreted by cancer cells from the same tumor type.

"The results of this research are highly significant in that they show that the ADAPT system can be deployed against multiple cancer types in various biological matrices and offers broad potential applications in biomarker discovery," said David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences, and an author of the study. "Further, we were able to show that in prostate cancer, ADAPT not only discriminated between cancer types but between subtypes of a specific lineage. We anticipate that this could potentially help inform treatment decisions based on the patient's specific molecular profile in prostate cancer and across a range of tumor types."

"The differences in the composition of the Endosomal Sorting Complex Required For Transport (ESCRT) pathway and associated complexes between exosomes derived from VCaP and LNCaP cells could point to them as novel biomarkers for these different prostate cancers," said Michael Famulok, Ph.D., University of Bonn (Germany), Life & Medical Sciences Institute (LIMES), Max Planck Fellow and co-author of the study. "We look forward to further investigating this potential and how the ADAPT system can be used to gain a greater understanding of the molecular composition of cells across tumor types."

The ADAPT Biotargeting System is Caris' proprietary unbiased profiling platform that uses a broad library of synthetically-manufactured molecules (aptamers) that bind to a wide range of biological targets and characterize complex biological systems in their native state, enabling them to profile biological samples at a systems-wide scale.

Thepaperwaspublishedonline on January 28 inNucleic Acids Research,andisavailableonlinehere and DOI:https://doi.org/10.1093/nar/gkaa034.

About Caris Life Sciences

Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions.

Story continues

Caris is also advancing precision medicine with Next Generation Profiling that combines its innovative service offerings, Caris Molecular Intelligence and ADAPT Biotargeting System, with its proprietary artificial intelligence analytics engine, DEAN, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.

Whole transcriptome sequencing with MI Transcriptome provides the most comprehensive and unique RNA analysis available on the market and covers all 22,000 genes, with an average of 60 million reads per patient, to deliver extremely broad coverage and high resolution into the dynamic nature of the transcriptome. Assessing the whole transcriptome allows us to dig deeper into the RNA universe to uncover and detect fusions, splice variants, and expression changes that provide oncologists with more insight and actionable information when determining treatment plans for patients.

Caris Pharmatech, a pioneer of the original Just-In-Time research system with the largest research-ready oncology network is changing the paradigm from the traditional physician outreach model to a real-time approach where patient identification is completed at the lab and the physician is informed so that the patient can be enrolled days earlier, and remain in the local physician's care, without having to travel to a large central trial site. This fundamentally redefines how pharmaceutical and biotechnology companies identify and rapidly enroll patients in precision oncology trials by combining Caris' highest quality industry leading large-scale molecular profiling services with Pharmatech's on-demand site activation and patient enrollment system.

Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visitwww.CarisLifeSciences.comor follow us on Twitter (@CarisLS).

Media Contact:Lindsey BailysGCI Healthlindsey.bailys@gcihealth.com +1-212-798-9884

View original content to download multimedia:http://www.prnewswire.com/news-releases/study-shows-that-caris-life-sciences-adapt-biotargeting-system-has-discovered-protein-expression-pattern-differences-between-two-prostate-cancer-patient-subpopulations-301002804.html

SOURCE Caris Life Sciences

Read the rest here:
Study Shows That Caris Life Sciences' ADAPT Biotargeting System Has Discovered Protein Expression Pattern Differences Between Two Prostate Cancer...

Editors note:Brooks Bell is the founder and CEO of her eponymous brand consulting firm.

RALEIGH A year ago, I was diagnosed with stage 3 colon cancer. Its been a tough year: 6 months of surgery and chemotherapy, followed by intense health recovery. I have made dramatic changes to my diet, fitness routine, and stress. This month, I received the news Ive been fantasizing about all year: Im cancer-free. A groundbreaking blood test determined that there is not a single molecule of my tumor cells currently in my blood. That, combined with a clear CT scan, means that there is a 95% chance that my cancer is gone and wont return. I am overjoyed.

When I received the news, Jes and I were just waking up in the Dominican Republic after celebrating our 21st anniversary together. I burst into tears of joy, and felt the burden of uncertainty lifting off my chest. It was a surreal moment. Id gotten accustomed to clawing back my health, questioning feelings of wellbeing.It was easy to imagine being one of the unlucky ones who has the cancer come back and spread (after all, I was already unlucky enough to get cancer in the first place).

This is what makes cancer so hard for many: even when youre done with your treatment, it takes years to fully relax again because up until now our existing technology has prevented us from knowing if the treatment was truly successful.

Not anymore.

The molecular test that I took is a cutting-edge technology calledNatera. It gives cancer patients personalized testing that involves doing ultra-deep DNA sequencing on your tumor cells, and then matching those to your blood to see if they are still floating around in your body.

It just got FDA breakthrough status in May, and I was the first patient at Duke Cancer Center to receive it.

I believe this test may be part of a paradigm shift in the cancer industry. Its a perfect example of the promise of personalized medicine and machine learning. It is going to give patients clear insight on whether their treatment has been successful, and maybe even if chemotherapy is even necessary for them. Its pretty incredible, and I am so lucky to be able to benefit from it. Go Duke! Go Natera!

Brooks Bells new cause. (Brooks Bell image)

I will be celebrating toasting my health and the50 Colonoscopies Under 50 honorees with my friends and supporters at The Colonoscopy Gala on Feb. 28 at CAM Raleigh. I would love for you to be there with me (especially if you are based in NC).

This may be the first ever Colonoscopy Gala in the history of time. A colonoscopy is the most effective way to protect yourself from colon cancer, and it deserves a night to be celebrated.

Itll be an evening to remember. We will have asuper talented chefdoing a five-course seated dinner for us, and you may be able to even get bring home a one-of-a-kind street-artist designedTushy Ottoman..

And of course, its for a good cause; all proceeds go to the astonishingly underfunded Colorectal Cancer Alliance.

Tickets are $175 each, and are available until Feb. 17. RSVP or donate here.

Brooks Bell: I finished my chemo treatment, feeling fantastic

Six months after cancer diagnosis, Brooks Bell appoints successor to run her brand consulting firm

Go here to see the original:
Brooks Bell: 'Groundbreaking blood test determined there is 95% chance my cancer is gone and won't return' - WRAL Tech Wire

Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq:IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics ThyraMIR miRNA classifier for evaluating indeterminate thyroid nodules retroactively to January 1, 2020. This determination increases the Medicare reimbursement for ThyraMIR from approximately $1800 to $3000 reflecting a re-evaluation of the technical and clinical performance of the test relative to other molecular tests in the market and their respective prices. Today, approximately 30% of the Companys ThyraMIR volume is attributable to Medicare eligible patients.

According to Jack Stover, CEO of Interpace, We are pleased with the thorough assessment given by CMS in evaluating one of our key products with the result of improved pricing for ThyraMIR. We believe this modification represents value-based pricing and reflects the critical impact ThyraMIR has on identifying a surgical need from surveillance. This price improvement is particularly noteworthy in light of our recent announcement surrounding the preliminary approval from CMS for a price increase in Interpaces biomarker companion product ThyGeNEXT.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and Commercial insurers, with more than 280 million members covered.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit of Interpace Biosciences that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpace Pharma Solutions Is a business unit of Interpace Biosciences that provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Pharma Solutions Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Story continues

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

See the original post here:
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay - Yahoo Finance

Dataintelo.com, has added the latest research on Personalized Medicines Market, which offers a concise outline of the market valuation, industry size, SWOT analysis, revenue approximation, and the regional outlook of this business vertical. The report precisely features the key opportunities and challenges faced by contenders of this industry and presents the existing competitive setting and corporate strategies enforced by the Personalized Medicines Market players.

As per the Personalized Medicines Market report, this industry is predicted to grow substantial returns by the end of the forecast duration, recording a profitable yearly growth in the upcoming years. Shedding light on brief of this industry, the report offers considerable details concerning complete valuation of the market as well as detailed analysis of the Personalized Medicines Market along with existing growth opportunities in the business vertical.

Request a sample Report of Personalized Medicines Market at: https://dataintelo.com/request-sample/?reportId=98645

Concepts and ideas in the report:Analysis of the region- based segment in the Personalized Medicines Market: As per the report, in terms of provincial scope, the Personalized Medicines Market is divided into USA, Europe, Japan, China, India and South East Asia. It also includes particulars related to the products usage throughout the geographical landscape. Data related to the evaluations held by all the zones mentioned as well as the market share registered by each region is included in the report. Sum of all the product consumption growth rate across the applicable regions as well as consumption market share is described in the report. The report speaks about consumption rate of all regions, based on product types and applications.

Brief of the market segmentation: As per the product type, the Personalized Medicines Market is categorized intoPM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

Furthermore, the market share of each product along with the project valuation is mentioned in the report. The report consists of facts related to every single products sale price, revenue, growth rate over the estimation time period.

The Personalized Medicines Market, according to the application spectrum, is categorized intoHospitals PharmaciesRetail PharmaciesDietary Care CentersOthers

Data pertaining the market share of each product application as well as estimated revenue that each application registers for is slated in the report.

Propelling factors & challenges: The report provides data concerning the forces influencing the commercialization scale of the Personalized Medicines Market and their effect on the revenue graph of this business vertical. Data pertaining to latest trends driving the Personalized Medicines Market along with the challenges this industry is about to experience in the upcoming years is mentioned in the report.

Ask for Discount on Personalized Medicines Market Report at: https://dataintelo.com/ask-for-discount/?reportId=98645

Implementing marketing tactics: Ideas about numerous marketing strategies implemented by the renowned shareholders with respect to product marketing is present in the report. Information related to the sales channels that companies select is also included in the report. Along with the dealers of these products, it also presents the summary of the top customers for the same.

Analysis of the major competitors in the market:An outline of the manufacturers active in the Personalized Medicines Market, consisting of3G BiotechQuest DiagnosticsLaboratory Corporation of AmericaAbbottAgendia NVAsuragen IncBecton DickinsonCardioDx Inc.Foundation MedicineQiagenSiemens HealthcareAmgenBristol-Myers SquibbGE HealthcarePfizerSanofi23andMeIlluminaalong with the distribution limits and sales area is reported. Particulars of each competitor including company profile, overview, as well as their range of products is inculcated in the report. The report also gives importance to product sales, price models, gross margins, and revenue generations. The Personalized Medicines Market report consists of details such as estimation of the geographical landscape, study related to the market concentration rate as well as concentration ratio over the estimated time period.

To Buy this report, Visit : https://dataintelo.com/checkout/?reportId=98645

Some of the Major Highlights of TOC covers:Personalized Medicines Regional Market Analysis Personalized Medicines Production by Regions Global Personalized Medicines Production by Regions Global Personalized Medicines Revenue by Regions Personalized Medicines Consumption by Regions

Personalized Medicines Segment Market Analysis (by Type) Global Personalized Medicines Production by Type Global Personalized Medicines Revenue by Type Personalized Medicines Price by Type

Personalized Medicines Segment Market Analysis (by Application) Global Personalized Medicines Consumption by Application Global Personalized Medicines Consumption Market Share by Application (2014-2019)

Personalized Medicines Major Manufacturers Analysis Personalized Medicines Production Sites and Area Served Product Introduction, Application and Specification Personalized Medicines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) Main Business and Markets Served

For More Information on this report, Request Inquiry At https://dataintelo.com/enquiry-before-buying/?reportId=98645

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataIntelo Name Alex Mathews Email [emailprotected] Website https://dataintelo.com Address 500 East E Street, Ontario, CA 91764, United States.

Read more:
Personalized Medicines Market, Share, Growth, Trends And Forecast To 2025 DataIntelo - Keep Reading

lacaosa via Getty Images

Prolon provides dieters with bars, soups, drinks, and supplements said to deliver the benefits of intermittent fasting byusing ingredients that "are not recognized as food by your body," according to its website.

Intermittent fasting of any kind has promising health benefits, including potentially slowing aging and diseases like cancer and diabetes.

But more research is needed before experts can be sure it's beneficial, or even not harmful, long term. Plus, it's unsafe for certain populations, like people at risk for eating disorders.

Dr. Caroline Apovian, professor of medicine in endocrinology, diabetes, nutrition and weight management at Boston University School of Medicine, previously told Insider that the only studies done on fasting diets have been small.

"We are getting insight into early time restricted eating but there is no solid research there yet it may be that a period of fasting during night hours is good for your metabolism but studies are still coming," Apovian said.

Read this article:
Oscars 2020: The science behind the wellness swag in nominee gift bags - Insider - INSIDER

Global Precision Medicine Market By Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Download Free PDF Sample Copy of Report@http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Competitive Analysis:

Theprecision medicine marketis highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Drivers

Market Restraints

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

SHORT Table of Contents

1.1. OVERVIEW OF THE GLOBAL PRECISION MEDICINE MARKET

1.2. CURRENCY AND PRICING

1.3. LIMITATION

1.4. MARKETS COVERED

2 MARKET SEGMENTATION

2.1. KEY TAKEAWAYS

2.2. ARRIVING AT THE GLOBAL PRECISION MEDICINE MARKET SIZE

2.3. GLOBAL PRECISION MEDICINE MARKET: RESEARCH SNAPSHOT

2.4. ASSUMPTIONS

3 MARKET OVERVIEW

3.1. DRIVERS

3.2. RESTRAINTS

3.3. OPPORTUNITIES

3.4. CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 GLOBAL PRECISION MEDICINE MARKET, BY TECHNOLOGY

6.1. OVERVIEW

6.2. BIG DATA ANALYTICS

6.3. BIOINFORMATICS

6.4. GENE SEQUENCING

6.5. DRUG DISCOVERY

6.6. COMPANION DIAGNOSTICS

6.7. OTHERS

7 GLOBAL PRECISION MEDICINE MARKET, BY APPLICATION

7.1. OVERVIEW

7.2. ONCOLGY

7.3. HEMATOLOGY

7.4. INFECTIOUS DISEASES

7.5. CARDIOLOGY

8 GLOBAL PRECISION MEDICINE MARKET, BY end-user

8.1. OVERVIEW

8.2. PHARMACEUTICALS

8.3. BIOTECHNOLOGY

9 GLOBAL PRECISION MEDICINE MARKET: COMPETITIVE LANDSCAPE

9.1. GLOBAL PRECISION MEDICINE MARKET: COMPANY SHARE ANALYSIS

9.2. MERGERS & ACQUISITIONS

9.3. NEW PRODUCT DEVELOPMENT & APPROVALS

9.4. EXPANSIONS

10 GLOBAL PRECISION MEDICINE MARKET, COMPANY PROFILES

10.1 Orion Health

10.2 ARIEL Precision Medicine, INC.

10.3 Metabolon, Inc.

10.4 Pfizer Inc.

10.5 Biocrates Life Sciences

10.6 Medtronic

10.7 NovartisAG

10.8 Quest Diagnostics Incorporated

10.9 F. Hoffmann-La Roche Ltd

10.10 Teva Pharmaceutical Industries Ltd

11 APPENDIX

12 ABOUT DATA BRIDGE MARKET RESEARCH

Get a Detail TOC @http://databridgemarketresearch.com/toc/?dbmr=global-precision-medicine-market

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Go here to read the rest:
Global Precision Medicine Market Analysis And Growth Forecast By Applications, Sales, Size, Types And Competitors By 2020-2026 - Reporting 99

Future Free Trade Agreementsand NHS

Trump has been openly expressing his interest to strike a free trade deal with the UK. The US president has also blamed the freeloading countries benefiting from US pharmaceutical research and extorting unreasonably low prices from US pharma reiterating that the US has great power over the trading partners. While the president denied the UKs NHS being on a trade talk table during the 70th anniversary of NATO, speculations about Trumps interest in the NHS do exist.

The major concern is that the US will want its pharma companies to gain greater commercial access to the NHS as part of a trade deal, which could force UK healthcare services into paying higher prices for US drugs.

The year 2020 will see continued pressure on the UKs medicines supply chain. While the biggest feardrug shortage associated with No Deal Brexit is out of the picture, at least during the transition period, the concerns surrounding the drug supply chain still exists.

If the UK leaves the European Medicines Agencys (EMAs) drug approval system and develops its own, Britain is at risk of getting delayed access to new medicines.

The announcement of the Medicines and Medical Devices Bill, which includes relaxing some regulations around clinical trials, speeding up the approval of innovative medicines, facilitating the prescription process of low-risk medicines and extending the UKs lead in personalized medicine and artificial intelligence, looks promising. Nevertheless, there is not much progress and clarity on what actions will be taken to bring these initiatives forward.

Another risk can derive from the failure to implement EU Clinical Trials Regulation within the UKs regulatory system, which could affect UK participation in multinational clinical trials.

Read more from the original source:
Brexit: It Will Take Years for the UK Healthcare Sector to Stabilize - MedicalExpo e-Magazine

On New Years Eve 2019, Drs. Kate Toyer and Tara Cashman sat down with their three kids and reviewed their escape plan.

The bushfires that had been burning for weeks were now threatening to overtake Batemans Bay, a coastal town in New South Wales, Australia, where the family lives and the veterinarians run a small animal clinic.

They had packed the car a month ago with food, water, and a few other essential itemsenough for the family members and their cat to live a short time away from home.

The calls came at 6 the next morning: Evacuate now.

We werent even asked to go to the evacuation center in town but to go straight to the beach, said Dr. Cashman, explaining they did, in fact, drive 6 miles to an evacuation center because of the better facilities. Thankfully, that was the right decision because the fires were so bad that those who evacuated to the beach actually had to stand in the water.

Fire season in Australia typically begins late in the year during the hot, dry summer when a lightning strike or human negligence sets a tree or patch of grass alight.

Bushfires are destructive and often deadly. In the southeast state of Victoria, 173 people died during the Black Saturday bushfires of 2009 that scorched more than a million acres of land and destroyed over 4,000 homes and other buildings.

The tragedy, one of the worst in Australias history, led to the creation of a task force to study all aspects of the governments bushfire strategy. That investigation resulted in several reforms, including early warning alerts similar to the kind Drs. Toyer and Cashman received.

The changes are widely credited with the relatively low number of human fatalities despite the unprecedented severity of the 2019-20 fire season. At press time in late January, the government reported the fires had killed more than 30 people, burned over 25 million acres, and destroyed roughly 3,000 houses.

Most of the fatalities and property loss occurred in New South Wales, where three American firefighters were killed in a plane crash on Jan. 23, one of whom was Ian McBeth, son of Dr. William McBeth, a member of the AVMA Food Safety Advisory Committee (see sidebar).

Batemans Bay was hit really hard early on, said Dr. Toyer, adding that 350 homes were destroyed. Most of the pictures you see in Western media, of the massive flames and burned-out landscapes, were taken in this area.

The clinic Dr. Toyer runs with her partner, Dr. Cashman, was, like their home, damaged but not destroyed. The practice operated off a generator for more than a month.

The South Coast has just been devastated since New Years Eve, said Dr. Julia Crawford, president of the Australian Veterinary Association. She estimates over 200 veterinary practices have been affected, about 90 seriously.

Support from around the world has been pouring in, including from the AVMA and American Veterinary Medical Foundation as well as other organizations, to support veterinary- and animal-focused relief efforts. The Morris Animal Foundation has allocated $1 million for scientific research grants to fund studies on how the regions wildfires have affected its native animals.

The most startling news about the bushfires has been the number of animals killed. Chris Dickman, PhD, a professor of ecology, conservation, and management of Australian mammals at the University of Sydney, estimates the fires will kill more than 800 million animals in New South Wales alone and impact a billion animals nationwide. By way of comparison, the Royal Society for the Prevention of Cruelty to Animals estimated up to 1 million wild and domesticated animals died during the 2009 Black Saturday brushfires.

As Dr. Dickman explained in a statement from the university, animals that survive the fires in the first instance by fleeing or going underground will return or reemerge into areas without the resources to support them. Others will fall victim to predators. Even for those birds or other animals able to flee to unaffected areas, they will rarely be able to successfully compete with animals already living there.

I think theres nothing quite to compare with the devastation thats going on over such a large area so quickly, Dr. Dickman said. Its a monstrous event in terms of geography and the number of individual animals affected.

We know that Australian biodiversity has been going down over the last several decades, and its probably fairly well known that Australias got the worlds highest rate of extinction for mammals. Its events like this that may well hasten the extinction process for a range of other species. So, its a very sad time.

Dr. Crawford described Dr. Dickmans estimates as a fair assessment.

I talked to veterinarians who assisted in the animal part of the response early on. They were waiting for injured wildlife to be brought in, but nothing came in, Dr Crawford said. We think these fires are so hot and burn so fast that probably 90% of these animals died immediately.

The deaths are just far more than we ever thought.

How to explain the catastrophic loss of animal life? How, even with advance warning, were the Australian government and people caught off guard by the severity of the fires?

In September, the same month the 2019-20 bushfire season started, the Australian Bureau of Meteorology issued a special climate statement warning of elevated fire dangers for New South Wales and the neighboring state of Queensland. Australia is three years into one of the worst droughts in decades. Then, in December, a heat wave broke the record for the highest nationwide average temperature, with some areas reaching up to 120 degrees Fahrenheit.

Together, these factors created an environmental tinderbox on a scale unlike anything the country had previously experienced.

The bushfires this season are unique in that multiple fires are occurring simultaneously and joining up to form superfires, explained Dr. Robert Johnson, director of Vets Beyond Borders, an Australian nonprofit that runs charitable veterinary programs in regions of Asia and the Pacific.

We are in the middle of a serious drought in Eastern Australia that has created an extraordinary amount of fuel for the fires, he said. What also sets these fires apart from previous ones is the fact that they have affected such a large proportion of populated areas. The amount of acreage burned is about eight times larger than the 2018 Californian wildfires.

With fire season expected to continue into the spring, the extent of the destruction is not yet fully understood.

Everyones still in response mode, Dr. Crawford said. The government puts the number of cattle and sheep deaths at more than 23,000, but she expects the final tally will be much, much higher.

When the last fire is finally out, Dr. Crawford worries about the economic fallout veterinary practices are sure to experience after months of interrupted services. She explained that Australian veterinarians generally do not charge to treat injured wildlife brought by the public to their clinics. Some practices provide as much as $3,000 in pro bono services weekly.

Thats all fine and well in ordinary times; we enjoy it, she said. But after a crisis like this, when your practice is almost burnt down, youre working from a generator, and the only patients youre seeing are wildlife, it becomes problematic from a cost standpoint.

Its summer here, Dr. Crawford added, and holidaymakers whod normally bring their pets to these coastal practices arent coming. Those veterinarians have lost that revenue, and its just devastating.

The country may see relief only temporarily, as conditions that caused the bushfires are predicted to continue, if not worsen, thanks to climate change.

Australias climate has warmed by just over 1 degree Celsius since 1910, leading to an increase in the frequency of extreme heat events, according to the Meteorology Bureaus State of the Climate 2018 report (PDF). At the same time, there has been a decline of around 11% in April-October rainfall in the southeast of Australia since the late 1990s. As a result, there has been a long-term increase in extreme fire weather and in the length of the fire season across large parts of Australia, according to the report.

Australia is projected to experience further increases in sea and air temperatures, with more hot days and marine heat waves and fewer cool extremes. Decreases in rainfall across southern Australia with more time in drought are also predicted.

Read more:
Australian bushfires a 'monstrous' event wreaking havoc on wildlife - American Veterinary Medical Association

People see the changes they expect in their pets, leading them to misattribute illness, good health, improvements, and declines.

Dr. Brennen McKenzie is a companion animal veterinarian working in California, the writer behind the SkeptVet blog, and the author of the recently published book, Placebos for Pets? The Truth About Alternative Medicine in Animals. He also is a columnist for Veterinary Practice News and past president of the Evidence-Based Veterinary Medicine Association. He wrote a 2014 JAVMA commentary on cognitive bias in clinical decisions (J Am Vet Med Assoc 2014:244;271-276).

In his book, Dr. McKenzie teaches how to evaluate the theories, methods, evidence, and safety records for myriad complementary or alternative therapies. The following interview has been edited for length and clarity.

A. I initially was thinking of it as a resource for pet owners, and I tried to write the book in language that is accessible to the general public. So, Im hoping that it will be an introduction to the general ideas about how we evaluate medical therapies for pets, whats the appropriate way to do that, whats the role of science in helping us to evaluate these thingsand also an appraisal of some of the more common alternative medical approaches that pet owners are likely to encounter. However, I also wanted it to be useful to veterinary professionals. All of the things that I talk about have extensive academic references available so that they can dig deeper if they want.

A. Its a fundamental feature of human cognition, and this is one thing I think all veterinarians should have some familiarity withthe history and philosophy of science and cognitive psychology. We all reason in ways that are kind of built into our brains.

I give a patient a medication, and a week later, that patients clinical symptoms resolve. I see a causal connection there and assume that the medication is responsible for the change. What we know from science is that its a lot more complicated than that. Were often doing multiple things at once. Diseases have a natural history where their symptoms wax and wane and can just resolve spontaneously. We may have the wrong diagnosis to begin with, and so when things dont go the way we expect, its not always because of what we did but because we were wrong about our assumptions.

Its very difficult for any of us, whether were veterinarians or not scientifically trained, to ignore our personal experience. And if a study comes out saying something that Ive been doing for 10 years and been selling to clients doesnt work, its difficult psychologically and cognitively for me to accept that my assessment is wrong and that Ive been doing the wrong thing.

A. Its complicated. One of the primary questions in science education today is, How do you change peoples minds about things? And were facing a crisis in terms of vaccine hesitancy (see story).

As a clinician seeing patients, I have a few key things that I try to focus on when I want to challenge somebodys perception. The first is I have to acknowledge that I understand their perception and validate their experiences and their reasoning.

If you begin by telling people that theyre ignorant or stupid, they wont listen to you. They may have perfectly rational reasons for a mistaken belief. So you begin by saying, I understand why you feel that this is a useful approach or why you feel that this therapy has been helpful to you. And then you introduce some potential reasons to doubt that.

I often talk about other cases in science where weve given up on therapies that clearly dont work anymore. Bloodletting is a great example where we believed in things for long periods of time and found them not to be true.

I also try to say, OK, lets look at this in terms of risk and benefit. Glucosamine is a widespread therapy for which theres very little evidence of efficacy, and yet, everyones using it. I say to people, Here are the reasons why I dont think it probably works. I also think that the risks are quite low, so I dont feel like its imperative that you give up that.

If you meet people halfway and work with their beliefs and their goals, I think theyre more likely to listen to you. Over time, you build a relationship with clients, and they come to trust you, and I think that gives you more credibility to tackle larger and more challenging beliefs.

It also makes a difference where that belief fits in their life. Im not going to talk to a client whos a chiropractor and try to convince them that chiropractic is not a valid therapy because thats embedded in their entire life, and thats not going to be a useful or successful interaction.

A. Almost certainly not, no. I think most people dont understand the theories behind the drugs that I give them, either. Most people are not interested in the deep background of medical therapies. What they hear are claims by practitioners of benefits, usually justified in terms of, Ive been doing this for 20 years, and it sure looks to me like it works. Anecdotal claims tend to be the easiest to offer and the most psychologically compelling, even though theyre the least reliable.

There are certainly some people who have a general worldview that is skeptical of science and technology and the pharmaceutical industry, which has certainly earned a great deal of skepticism. And I think that alternative medicine fits into that worldview. I think also that conventional medicine, particularly for humans, has a lot of serious problems in terms of how we communicate with people, how we manage their lives and their needs. Weve become very siloed and segmented into subspecialties and very technologically focused. I think there are a lot of things wrong with how we offer health care to people, and the environments and conversations that alternative practitioners often have with people address a lot of those concerns and those problems. I do think that alternative medicine fits into peoples lives in an ideological and philosophical way.

A. I do offer some fairly simple guidelines in the book. One is that no single study is ever definitive because its impossible to completely eliminate bias. If theres only one study, you should still be a bit skeptical. Larger studies are better than smaller studies. Any study that does not effectively have a placebo arm and doesnt hide from both the owners of the pets and also the investigators or veterinarians which therapy each pet is getting is probably going to be biased and not reliable. So, there are some very simple rules that you can apply.

I think, honestly, the onus is on veterinarians to be better at understanding how to appraise a clinical trial and then to talk to owners. Even in the absence of large-scale, definitive, high-quality evidence, I do think we can look at these therapies and the reasoning behind them and the evidence for them and make sound, honest recommendations one way or anotherthat dont just rely on anecdotes.

Theres a method that I try to teach in the book for approaching things, so even if there are things that I dont cover in the book, I hope that itll be useful to people in terms of finding a structured, reliable way to approach new things.

As a veterinarian, Im hearing about new supplements and new therapies all the time, and many of them dont have a lot of research evidence. But I dont think we have to say to our clients, I dont know, theres nothing I can do, take your best guess. I think we can use a systematic, science-based approach to help guide and counsel our patients.

Read more from the original source:
Veterinarian works to reduce caregiver placebo effect | American Veterinary Medical Association - American Veterinary Medical Association

AMANA COLONIES, Iowa (KCRG) - Her whole life, Dr. Barbara Roland has loved animals. That love inspired her career path. Since getting her Doctor of Veterinary Medicine degree in 1987, Roland has treated animals, most recently at the Newton Animal Clinic.

Now that Roland is semi-retired, she continues to save animals' lives by using her knowledge and skills as a veterinarian at Safe Haven of Iowa County. Its a no-kill shelter that serves not only local strays but animals from around the country.

Its mission is to, rescue, protect, rehabilitate and find good homes for dogs and cats in Iowa County. Secondly, to significantly reduce the overpopulation of stray dogs and cats, and improve the lives of humans and the lives of pets through public education and sponsoring low/no-cost spay and neuter programs.

Rolands home has always been the Amana Colonies. That's also where the Safe Haven of Iowa County is, housed in the former Krauss furniture building. Built in 1956 by Roland's relatives, Virginia Marie Hoppe donated the building to the animal rescue in 2012 after the family furniture store closed down.

I know they're all smiling down in heaven at the work we are doing here because our family has always loved animals, Roland said, with a smile. Especially Virginia, this would make her so happy.

In the past couple of years, the Safe Haven of Iowa County added a surgery suite, where Roland's services have helped thousands of animals. She volunteers her time and talents to complete surgery on the rescue animals, all for free.

She's not just a regular vet either, she's a skilled surgeon, Kimberly Buresh, 15-year volunteer and board president, said. Since we've had our surgery suite, and have our volunteer vet here, our adoptions have doubled, especially with the cats, because we're able to get them in, spayed, neutered, so much quicker because we can do that in house.

Buresh said it normally costs around $100 for a spay or neuter procedure, and scheduling is up to other clinics. As more healthy animals get adopted, that frees up space to take in more strays. The shelter can also take on more complicated health cases.

Freddy the cat, at the time of KCRG-TV9s visit, went from near-death to happy and healthy in just days from Rolands care.

He's just one of the countless other animals, helped by Roland, living out her life's dream to help animals, even, without the promise of a paycheck.

I'm glad we were able to save his life," Roland said.

Read the original here:
9 Who Care: Veterinarian uses a lifetime of experience, passion to heal shelter animals - KCRG

Radiation therapy to treat cancer can be grueling, requiring consecutive days of therapy over days or weeks.

When you talk to patients about coming in for 35 treatments, or seven weeks of daily therapy, usually their face kind of sags in disappointment or perhaps apprehension, says Keith Cengel, a radiation oncologist at Penns Perelman School of Medicine.

Thats why the promise of whats known as FLASH radiation therapy, in which a full dose of radiation is given in less than a second, is so great.

But FLASH remains in its infancy, with researchers still unsure about how the all-in-one-go approach stacks up against traditional methods. To test its effectiveness at killing cancer cells and sparing normal cells, researchers from Penn Medicine and Penns School of Veterinary Medicine are pairing their expertise in a clinical trial applying the cutting edge of human medicine in dogs.

From a veterinary standpoint, this is a type of radiation that is still very, very new in human medicine, says Jennifer Huck, a veterinary surgeon at Penn Vet who is partnering with Cengel on the trial. So theres a lot of excitement in the veterinary realm about this.

In the trial, dogs with osteosarcoma, a form of bone cancer that people, especially children, can also develop, receive the FLASH radiation. They then go on to receive the standard of care for osteosarcoma, which entails amputating the affected limb and, in some cases, at the owners and veterinarians discretion, following up with chemotherapy to slow the growth of microscopic disease in other areas of the body that may already be present at the time of diagnosis.

The study is not designed to confer a direct benefit to the dogs enrolled, though the clinicians arent ruling out that possibility. The main intent, they say, is to understand whats happening to the cells and tissuesboth cancerous and normalthat the therapy targets. In labs both at Penn Medicine and Penn Vet, researchers are studying samples from the amputated limb to assess the effects of the treatment.

Were looking at gene expression profiling, markers of cell death and cell division, and analyzing immune cell populations to just get a survey of what the tumor and normal tissue look like, says Cengel.

The work is moving quickly. The project aims to enroll 20 dogs. The researchers started late in 2019 and have already treated seven. Several more await treatment or evaluation.

I think that we greatly underestimate the excitement of pet owners to be involved in research and to be able to contribute to a project like this, says Huck. The treatment that their pet receives is ultimately no different from any other standard of care that we would offer to any pet that comes in with osteosarcoma, whether theyre on the study or not, so I think that also gives them comfort.

Four-year-old Milo, a leggy SaintBernard, is one such participant. Owner Tim Gordon describes him as perfect.

Hes a great dog, great with the kids, great with our other dog, Gordon says. Hes adjusted to everything weve thrown at him.

Starting around Thanksgiving, however, the family, which includes Tims wife, Trista, and their 8-year-old son and 11-year-old daughter, could tell Milo was feeling out of sorts.

We noticed he was limping around a bit and being really lethargic, says Gordon. At first they attributed his behavior to the influx of guests they had around the holiday. Then they started to worry about hip dysplasia. But in early December, Gordons 8-year-old son noticed a bulge in Milos leg near his paw.

The family brought their pet to the veterinarian expecting to learn he had a sprain or even a broken bone, but a graver diagnosis came back: osteosarcoma. Wanting to participate in a clinical trial, the family made several trips to Penn Vet from their home near Baltimore to get him evaluated and then for the radiation, limb removal surgery, and follow up.

Not only did participating in the clinical trial help the Gordons cover some of the costs of treatment, but they also appreciated the opportunity to contribute to studies that may advance cancer treatment.

That kept us going, says Trista Gordon. Even my daughter kept saying that Milo could help other dogs or even children who have this disease. That eased her sadness in a way.

That was especially resonant since Tim Gordon lost his mother to osteosarcoma. I knew what we went through with my mom and what she went through, he says. The thought definitely went through our minds that maybe we can help benefit other families by participating.

The goal of radiation therapy, like all cancer-killing strategies, is to unleash a strong assault on tumor cells while sparing normal cells as much as possible. And while researchers have tweaked other facets of radiation, such as how it is aimed and how the dose is fractionated, or spread over days or weeks, its only very recently that the FLASH approach has opened the possibility of giving a full dose all at once.

Traditional radiation therapy uses the energy of photons, or X-rays, to kill cancer cells. Early work with FLASH radiation has used electrons to deliver that energy, but those can only penetrate tumors that are a few centimeters deep.

In January, Cengel and Penn Medicine colleagues including Constantinos Koumenis and James Metz reported on FLASH radiation using protons, which can penetrate deeper than electrons to allow treatment of the vast majority of human tumors by beaming in radiation from outside the body to target tumors and to spare normal tissues.

Our initial results are very promising that FLASH proton radiotherapy may improve outcomes significantly. However, even if this approach isnt more effective or less toxic than what we have been doing, says Cengel, if we end up with exactly the same results but with a single treatment, it is still tremendously beneficial in terms of the patient experience.

Provided the dog trial goes well, Huck and Cengel hope to continue working quickly to translate their findings to benefit more patients, both human and canine.

And while a diagnosis of cancer and subsequent treatment is never easy, the Gordon family is grateful for how well Milo is doing.

Each day hes surpassing our expectations, honestly, says Trista Gordon. Hes getting back to his playful self.

Keith Cengel is an associate professor of radiation oncology at the University of Pennsylvania.

Jennifer Huck is an assistant professor of clinical surgery at the University of Pennsylvania School of Veterinary Medicine.

Go here to see the original:
Treatment in a FLASH - Penn: Office of University Communications

Professor/Associate Professor/Assistant Professor (Evidence-based Veterinary Medicine) in the Department of Infectious Diseases and Public Health[Ref. C/595/09]

City University of Hong Kong is a dynamic, fast-growing university that is pursuing excellence in research and professional education.As a publicly-funded institution, the University is committed to nurturing and developing students talents and creating applicable knowledge to support social and economic advancement. The University has nine Colleges/Schools. As part of its pursuit of excellence, the University aims to recruitoutstanding scholarsfrom all over the world in various disciplines, includingbusiness, creative media, data science, energy and environment, engineering, humanities and social sciences, law, science, veterinary medicine and life sciences.

The Department of Infectious Diseases and Public Health was established in July 2017. Its mission is to achieve and sustain excellence in teaching and research in veterinary studies through advancing the understanding of the interconnectivity of animal and human health. This is an opportunity to join a vibrant diverse international team shaping the future of veterinary education and research in the region. The Department plays a key role in teaching students in the Bachelor of Veterinary Medicine and providing postgraduate research training. Departmental academic staff members undertake teaching and research across their areas of specialty, and are actively engaged in enhancing the profile and effectiveness of veterinary training, public health and applied research through partnership and strengthening links with industry, business, commerce and other institutions locally and internationally.

Applications and nominations are invited for the above posts:

Duties

The appointee is expected to support the overall academic mission of the University and facilitate further development of research and teaching activities including delivery of problem-based learning courses of the Department; contribute to the Departments evidence-based veterinary medicine (EBVM) teaching, both at undergraduate and postgraduate levels and through establishing a research programme, especially with the horse racing industry in Hong Kong.

Requirements

A Doctor of Veterinary Medicine degree or an equivalent veterinary degree, preferably registrable in Hong Kong, with evidence of further postgraduate education in the form of Diplomate status in a recognized specialty board and/or academic qualifications at doctorate level in EBVM or Veterinary Epidemiology. A PhD in a relevant discipline (veterinary medicine, animal science, biology) or equivalent is highly preferred. Applicants must have demonstrable evidence of research success including publications in internationally-recognised journals and the ability to obtain research funding, and strong interpersonal skills with the ability to work collaboratively as a member of an academic team. Experience in tertiary-level curriculum development and teaching in associated subject areas, such as veterinary epidemiology, and/or experience in equine epidemiological research would be an asset.

Salary and Conditions of Service

Remuneration package will be driven by market competitiveness and individual performance. Excellent fringe benefits include gratuity, leave, medical and dental schemes, and relocation assistance (where applicable). Initial appointment will be made on a fixed-term contract.

Information and Application

Further information on the posts and the University is available athttp://www.cityu.edu.hk, or from the Department of Infectious Diseases and Public Health, City University of Hong Kong, Tat Chee Avenue, Kowloon Tong, Hong Kong (email :ssthilai@cityu.edu.hkorchhung@cityu.edu.hk).

To apply, please submit an online application athttp://jobs.cityu.edu.hk, and include a current curriculum vitae, a cover letter, research and teaching statements based on the position. Nominations can be sent directly to the Department (email:cardith.hung@cityu.edu.hk).Applications and nominations will receive full consideration until the positions are filled. Only shortlisted applicants will be contacted; and those shortlisted for the post of Assistant Professor will be requested to arrange for at least 3 reference reports sent directly by the referees to the Department, specifying the position applied for. The University's privacy policy is available on the homepage.

City University of Hong Kong is an equal opportunity employer and we are committed to the principle of diversity. Personal data provided by applicants will be used for recruitment and other employment-related purposes.

Worldwide recognition ranking 52nd, and 4th among top 50 universities under age 50 (QS survey 2020); 1st in Engineering/Technology/Computer Sciences in Hong Kong (ARWU survey 2016); and 2nd Business School in Asia-Pacific region (UT Dallas survey 2017).

See the original post:
Professor/Associate Professor/Assistant Professor (Evidence-based Veterinary Medicine) job with CITY UNIVERSITY OF HONG KONG | 195549 - Times Higher...